1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

  • July 2015
  • 179 pages
  • GBI Research
Report ID: 3172453

Summary

Table of Contents

Search Inside

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

Summary

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets.

This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex. However, current treatment regimens are often associated with limited long-term efficacy, complex and inconvenient dosing regimens, and undesirable side effects such as weight gain and hypoglycemia (low blood glucose levels).

Scope

- Metformin monotherapy will remain the first-line pharmacotherapy for T2DM.
- The emergence of several new drug classes over the past decade, namely the Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP-4) inhibitors, and Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors, has led to considerable market growth.
- Which products lead these drug classes and what threats do they face from the pipeline?
- How will the continued uptake of newer drug classes impact established drug classes such as the sulfonylureas and thiazolidinediones?
- Leading insulin therapy Lantus (insulin glargine) recently lost patent protection in most major markets.
- Will recently approved insulin therapies such as Tresiba (insulin degludec) and Toujeo (insulin glargine) be able to capture a significant portion of Lantus’ market share?
- The pipeline is large and highly innovative, comprising a range of molecule types and molecular targets.
- How do different molecule types and molecular targets compare in terms of average failure rate, clinical trial duration, and clinical trial size?
- Which late-stage pipeline molecules show the most promise and how will they impact the treatment algorithm over the forecast period?
- Which late-stage pipeline molecules are expected to generate the highest revenues?
- Over the 2014–2021 forecast period, the global T2DM market is expected to increase in value at a CAGR of 7.5% from $23.5 billion to $39.0 billion.
- How do prevalence, diagnosis, and treatment patterns vary in the eight major markets?
- Which factors will drive market growth most significantly?
- Strategic consolidation activity in T2DM is considerable, with US-based companies being key players.
- Do T2DM products tend to attract high levels of investment?

Reasons to buy

- Understand the clinical context of the T2DM indication and the global burden of the disease by considering epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, disease classification, disease prognosis, and treatment options
- Appreciate the current T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need
- Identify key pipeline trends in molecule type and molecular target
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target
- Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan
- Discover how strategic consolidations have shaped the current T2DM pipeline and marketed products landscapes

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025 Summary COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow ...

OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 Summary Nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • August 2017
    75 pages
  • Therapy  

    Monoclonal Anti...  

  • United States  

View report >

Vaccine Market and Influenza Statistics in India

  • August 2017
    6 pages
  • Vaccine  

    Influenza  

    Diabetes  

  • India  

    United States  

View report >

Anti-Infective Market in the US

  • August 2017
    9 pages
  • Anti-Infective  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.